Published in Annals of Internal Medicine · View the paper (DOI)
A systematic review found that cannabis products with higher THC concentration provide small improvements in pain and function, but at the cost of increased risks of common adverse events. CBD-only formulations showed no benefits. Long-term research is needed to guide patients and policymakers.
Coverage from 2 institutions